You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. SUNSHINE BIOPHARMA INC

Sunshine Biopharma Inc XNAS: SBFM

Sunshine Biopharma Inc Live Share Price Today, Share Analysis and Chart

Download real time

2.12 -0.01 (-0.47%)

84.00% Fall from 52W High

18,380 XNAS Volume

XNAS 26 Mar, 2025 12:08 PM (EDT)

Watchlist

Portfolio

Share

Sunshine Biopharma Inc Key Metrics

Select

Market Capitalization

Low in industry
5.7

PE TTM

Negative PE TTM
-1.4

Price to Book

Low in industry
0.2

Institutional holding current Qtr %

Low in industry
0.8

Revenue Growth Qtr YoY %

Below industry Median
41.6

Operating Revenue growth TTM %

Below industry Median
61.9

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-83.9

Net Profit TTM Growth %

High in industry
84.2

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-13.1

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-14.9

Piotroski Score

Below industry Median
3

Rel Perf vs Sector quarter%

-38.8

ROE Annual %

Negative ROE Annual %
-21

RoA Annual %

Negative RoA Annual %
-15.9
All financials are in USD Million and price data in USD
VIEW MORE

9

S

12

W

1

O

1

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Sunshine Biopharma Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '23Dec '24Dec '25050100Actual RevenueAvg. Estimate
Hit

Sunshine Biopharma Inc's Revenue was higher than average estimate 1 time in past 1 year

EPS forecast

Current EPS
-380
Avg. Estimate
-4.1
Low Estimate
-4.1
High Estimate
-4.1
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 98.9% in FY24

Consensus Recommendation

1 ANALYST Recommendations
STRONG BUY

Created with Highcharts 7.2.21Strong Buy

The consensus recommendation from 1 analyst for Sunshine Biopharma Inc is STRONG BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Sunshine Biopharma Inc Stock Analysis

Sunshine Biopharma Inc stock analysis with key metrics, changes, and trends.

Sunshine Biopharma Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$24.09 M18.38%positive

Annual Revenue rose 18.38%, in the last year to $24.09 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit$4.51 M83.17%positive

Annual Net Profit rose 83.17% in the last year to $4.51 M. Its sector's average net profit growth for the last fiscal year was -32.46%.

Price to Earning Ratio-1.36-negative

Price to Earning Ratio is -1.36, which is negative.

Stock Price$2.12-63.19%negative

Stock Price fell 63.19% and underperformed its sector by 70.18% in the past year.

Quarterly Revenue$8.44 M41.59%positive

Quarterly Revenue rose 41.59% YoY to $8.44 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit$1.2 M83.86%negative

Quarterly Net profit fell 83.86% YoY to $1.2 M. Its sector's average net profit growth YoY for the quarter was -47.31%.

Debt to Equity Ratio0.03-positive

Debt to Equity Ratio of 0.03 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-21.04 %-21.04%negative

Return on Equity(ROE) for the last financial year was -21.04%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Interest Coverage Ratio-28.94-negative

Interest Coverage Ratio is -28.94, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding0.76 %-0.53%negative

Institutional Holding decreased by 0.53% in the last quarter to 0.76.

VIEW LESS


Loading data..

Sunshine Biopharma Inc - Company Profile

What does Sunshine Biopharma Inc do?

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.

Sunshine Biopharma Inc Management structure

All Gross Remunerations are in USD
Mr. Michel Roy
Chief Commercial Officer
-
2025
Gross Remuneration
Year

Sunshine Biopharma Inc Board of directors

All Gross Remunerations are in USD
Dr. Abderrazzak Merzouki, PhD
Chief Science Officer and Director
-
2024
Gross Remuneration
Year
Dr. Steve N. Slilaty, PhD
President and Chairman of the Board; Chief Executi
-
2024
Gross Remuneration
Year

Sunshine Biopharma Inc FAQ

How is Sunshine Biopharma Inc today?
Sunshine Biopharma Inc today is trading in the red, and is down by -0.47% at 2.12.
Sunshine Biopharma Inc is currently trading down -0.47% on an intraday basis. In the past week the stock rose 0.95%. stock has been down -34.57% in the past quarter and fell -63.19% in the past year. You can view this in the overview section.